Veracyte, Inc. (NASDAQ:VCYT) Stock Has Consensus Price Target of $55.78

Shares of Veracyte, Inc. (NASDAQ:VCYT) have received a consensus rating of “Hold” from the twelve ratings firms that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $44.50.

Several analysts recently weighed in on the stock. Weiss Ratings downgraded shares of Veracyte from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, September 24th. UBS Group lowered their price objective on shares of Veracyte from $65.00 to $35.00 and set a “buy” rating on the stock in a research report on Monday. Canaccord Genuity Group decreased their price target on Veracyte from $60.00 to $50.00 and set a “hold” rating for the company in a report on Monday, August 3rd. Wall Street Zen downgraded shares of Veracyte from a “buy” rating to a “hold” rating in a research report on Saturday, November 7th. Finally, Morgan Stanley cut their price target on shares of Veracyte from $47.00 to $44.00 and set an “underweight” rating for the company in a report on Tuesday, August 4th.

Insider Transactions at Veracyte

In related news, Director Karin Eastham sold 14,850 shares of the stock in a transaction on Tuesday, October 27th. The stock was sold at an average price of $50.00, for a total transaction of $742,500.00. Following the sale, the director owned 10,247 shares of the company’s stock, valued at $512,350. This trade represents a 59.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jens Holstein sold 7,500 shares of Veracyte stock in a transaction dated Tuesday, October 27th. The stock was sold at an average price of $50.00, for a total transaction of $375,000.00. Following the sale, the director owned 27,471 shares of the company’s stock, valued at approximately $1,373,550. This trade represents a 21.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 62,609 shares of company stock worth $2,858,904 in the last quarter. Insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. bought a new stake in Veracyte during the second quarter worth approximately $792,058,000. Dimensional Fund Advisors LP boosted its stake in shares of Veracyte by 2.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,881,090 shares of the biotechnology company’s stock valued at $92,787,000 after buying an additional 80,614 shares during the period. William Blair Investment Management LLC grew its holdings in shares of Veracyte by 89.2% during the 3rd quarter. William Blair Investment Management LLC now owns 2,709,212 shares of the biotechnology company’s stock valued at $124,732,000 after acquiring an additional 1,277,616 shares in the last quarter. GW&K Investment Management LLC grew its holdings in shares of Veracyte by 70.1% during the 3rd quarter. GW&K Investment Management LLC now owns 2,409,303 shares of the biotechnology company’s stock valued at $110,924,000 after acquiring an additional 992,760 shares in the last quarter. Finally, First Trust Advisors LP increased its stake in shares of Veracyte by 64.9% in the first quarter. First Trust Advisors LP now owns 2,117,046 shares of the biotechnology company’s stock worth $68,190,000 after acquiring an additional 833,543 shares during the last quarter.

More Veracyte News

Here’s some of the latest news about VCYT:

• Neutral Sentiment: Stephens cut its price target to $40 from $55 but maintained an “overweight” rating; Piper Sandler lowered its target to $30 from $54, also keeping “overweight.” The revised targets still imply potential upside from the cited $25.11 share price, but the sizable reductions reflect a more cautious outlook. Tickerreport article
• Negative Sentiment: A securities-law firm announced an investigation related to Veracyte’s disclosure of Decipher Prostate growth risks. The notice points to below-expectation test volume and narrowed 2026 revenue guidance, which could keep investor attention on execution and legal risk. Investigation notice
• Negative Sentiment: UBS issued a pessimistic forecast for Veracyte, though the supplied report does not provide its specific estimates. Wall Street Zen also cut its rating to “Hold.” UBS forecast report

Veracyte Stock Performance

Shares of VCYT opened at $25.11 on Thursday. The stock has a market capitalization of $2.03 billion, a PE ratio of 15.83 and a beta of 1.98. The company has a 50 day moving average price of $42.98 and a 200-day moving average price of $42.59. Veracyte has a fifty-two week low of $21.91 and a fifty-two week high of $60.91.

Veracyte (NASDAQ:VCYT) last issued its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported $0.51 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.10. The business had revenue of $151.75 million for the quarter, compared to analyst estimates of $147.13 million. Veracyte had a net margin of 21.80% and a return on equity of 8.99%. Veracyte’s revenue for the quarter was up 15.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.51 EPS. Equities research analysts forecast that Veracyte will post 1.32 EPS for the current year.

About Veracyte

Veracyte, Inc. is a genomic diagnostics company that develops tests to help clinicians diagnose disease and guide treatment decisions, with a focus on cancer and other complex conditions. Its tests analyze biological samples to provide information that can help distinguish between conditions and assess disease risk. The company’s portfolio includes Afirma for thyroid nodule assessment, Decipher for prostate cancer, Prosigna for breast cancer, and Percepta for lung cancer. Veracyte also offers Envisia, a genomic test that supports the diagnosis of idiopathic pulmonary fibrosis and other forms of interstitial lung disease.